Horizon Therapeutics Public (HZNP) Short Interest Ratio & Short Volume

Short interest is the volume of Horizon Therapeutics Public shares that have been sold short but have not yet been covered or closed out. As of September 15th, investors have sold 7,100,000 shares of HZNP short. Learn More on Horizon Therapeutics Public's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HZNP shares currently have a short interest ratio of 3.0. Learn More on Horizon Therapeutics Public's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Horizon Therapeutics Public: Nomura Holdings Inc., P Schoenfeld Asset Management LP, PSquared Asset Management AG, Bardin Hill Management Partners LP, BTG Pactual Global Asset Management Ltd, Highbridge Capital Management LLC, Picton Mahoney Asset Management, BCK Capital Management LP, and Equitec Proprietary Markets LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Horizon Therapeutics Public saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 7,100,000 shares, a decrease of 25.1% from the previous total of 9,480,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies compare to Horizon Therapeutics Public: Royalty Pharma plc (3.27%), Jazz Pharmaceuticals plc (5.41%), Elanco Animal Health Incorporated (2.52%), Mirati Therapeutics, Inc. (6.26%), Zoetis Inc. (0.80%), Bristol-Myers Squibb (1.73%), Genmab A/S (0.37%), Alnylam Pharmaceuticals, Inc. (2.22%), BioMarin Pharmaceutical Inc. (1.62%), Teva Pharmaceutical Industries Limited (1.03%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($8.05 billion), T-Mobile US, Inc. ($3.94 billion), Charter Communications, Inc. ($3.77 billion), Occidental Petroleum Co. ($3.27 billion), Tractor Supply ($2.29 billion), Celsius Holdings, Inc. ($2.20 billion), Rivian Automotive, Inc. ($2.10 billion), Moderna, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($1.90 billion), and T. Rowe Price Group, Inc. ($1.90 billion). View all of the most shorted stocks.

Short selling HZNP is an investing strategy that aims to generate trading profit from Horizon Therapeutics Public as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Horizon Therapeutics Public occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HZNP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HZNP, twice per month. The most recent reporting period available is September, 15 2023.